Biological and biochemical basis of the differential efficacy of first and second generation somatostatin receptor ligands in neuroendocrine neoplasms

Federico Gatto, Federica Barbieri, Marica Arvigo, Stefano Thellung, Jessica Amarù, Manuela Albertelli, Diego Ferone, Tullio Florio

Research output: Contribution to journalReview article

Abstract

Endogenous somatostatin shows anti-secretory effects in both physiological and pathological settings, as well as inhibitory activity on cell growth. Since somatostatin is not suitable for clinical practice, researchers developed synthetic somatostatin receptor ligands (SRLs) to overcome this limitation. Currently, SRLs represent pivotal tools in the treatment algorithm of neuroendocrine tumors (NETs). Octreotide and lanreotide are the first-generation SRLs developed and show a preferential binding affinity to somatostatin receptor (SST) subtype 2, while pasireotide, which is a second-generation SRL, has high affinity for multiple SSTs (SST5 > SST2 > SST3 > SST1 ). A number of studies demonstrated that first-generation and second-generation SRLs show distinct functional properties, besides the mere receptor affinity. Therefore, the aim of the present review is to critically review the current evidence on the biological effects of SRLs in pituitary adenomas and neuroendocrine tumors, by mainly focusing on the differences between first-generation and second-generation ligands.

Original languageEnglish
Article number3940
JournalInternational Journal of Molecular Sciences
Volume20
Issue number16
DOIs
Publication statusPublished - Aug 2 2019

Fingerprint

neoplasms
Somatostatin Receptors
Ligands
ligands
Neoplasms
Neuroendocrine Tumors
affinity
Pituitary Neoplasms
Somatostatin
Tumors
Artificial Receptors
tumors
Octreotide
Cell growth
biological effects
Research Personnel
Growth

Keywords

  • Neuroendocrine tumors
  • Pituitary adenomas
  • Somatostatin receptor ligands
  • Somatostatin receptors

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Biological and biochemical basis of the differential efficacy of first and second generation somatostatin receptor ligands in neuroendocrine neoplasms. / Gatto, Federico; Barbieri, Federica; Arvigo, Marica; Thellung, Stefano; Amarù, Jessica; Albertelli, Manuela; Ferone, Diego; Florio, Tullio.

In: International Journal of Molecular Sciences, Vol. 20, No. 16, 3940, 02.08.2019.

Research output: Contribution to journalReview article

@article{699e9286ace340bb81c516ef6f03bf5a,
title = "Biological and biochemical basis of the differential efficacy of first and second generation somatostatin receptor ligands in neuroendocrine neoplasms",
abstract = "Endogenous somatostatin shows anti-secretory effects in both physiological and pathological settings, as well as inhibitory activity on cell growth. Since somatostatin is not suitable for clinical practice, researchers developed synthetic somatostatin receptor ligands (SRLs) to overcome this limitation. Currently, SRLs represent pivotal tools in the treatment algorithm of neuroendocrine tumors (NETs). Octreotide and lanreotide are the first-generation SRLs developed and show a preferential binding affinity to somatostatin receptor (SST) subtype 2, while pasireotide, which is a second-generation SRL, has high affinity for multiple SSTs (SST5 > SST2 > SST3 > SST1 ). A number of studies demonstrated that first-generation and second-generation SRLs show distinct functional properties, besides the mere receptor affinity. Therefore, the aim of the present review is to critically review the current evidence on the biological effects of SRLs in pituitary adenomas and neuroendocrine tumors, by mainly focusing on the differences between first-generation and second-generation ligands.",
keywords = "Neuroendocrine tumors, Pituitary adenomas, Somatostatin receptor ligands, Somatostatin receptors",
author = "Federico Gatto and Federica Barbieri and Marica Arvigo and Stefano Thellung and Jessica Amar{\`u} and Manuela Albertelli and Diego Ferone and Tullio Florio",
year = "2019",
month = "8",
day = "2",
doi = "10.3390/ijms20163940",
language = "English",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "16",

}

TY - JOUR

T1 - Biological and biochemical basis of the differential efficacy of first and second generation somatostatin receptor ligands in neuroendocrine neoplasms

AU - Gatto, Federico

AU - Barbieri, Federica

AU - Arvigo, Marica

AU - Thellung, Stefano

AU - Amarù, Jessica

AU - Albertelli, Manuela

AU - Ferone, Diego

AU - Florio, Tullio

PY - 2019/8/2

Y1 - 2019/8/2

N2 - Endogenous somatostatin shows anti-secretory effects in both physiological and pathological settings, as well as inhibitory activity on cell growth. Since somatostatin is not suitable for clinical practice, researchers developed synthetic somatostatin receptor ligands (SRLs) to overcome this limitation. Currently, SRLs represent pivotal tools in the treatment algorithm of neuroendocrine tumors (NETs). Octreotide and lanreotide are the first-generation SRLs developed and show a preferential binding affinity to somatostatin receptor (SST) subtype 2, while pasireotide, which is a second-generation SRL, has high affinity for multiple SSTs (SST5 > SST2 > SST3 > SST1 ). A number of studies demonstrated that first-generation and second-generation SRLs show distinct functional properties, besides the mere receptor affinity. Therefore, the aim of the present review is to critically review the current evidence on the biological effects of SRLs in pituitary adenomas and neuroendocrine tumors, by mainly focusing on the differences between first-generation and second-generation ligands.

AB - Endogenous somatostatin shows anti-secretory effects in both physiological and pathological settings, as well as inhibitory activity on cell growth. Since somatostatin is not suitable for clinical practice, researchers developed synthetic somatostatin receptor ligands (SRLs) to overcome this limitation. Currently, SRLs represent pivotal tools in the treatment algorithm of neuroendocrine tumors (NETs). Octreotide and lanreotide are the first-generation SRLs developed and show a preferential binding affinity to somatostatin receptor (SST) subtype 2, while pasireotide, which is a second-generation SRL, has high affinity for multiple SSTs (SST5 > SST2 > SST3 > SST1 ). A number of studies demonstrated that first-generation and second-generation SRLs show distinct functional properties, besides the mere receptor affinity. Therefore, the aim of the present review is to critically review the current evidence on the biological effects of SRLs in pituitary adenomas and neuroendocrine tumors, by mainly focusing on the differences between first-generation and second-generation ligands.

KW - Neuroendocrine tumors

KW - Pituitary adenomas

KW - Somatostatin receptor ligands

KW - Somatostatin receptors

UR - http://www.scopus.com/inward/record.url?scp=85071167624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071167624&partnerID=8YFLogxK

U2 - 10.3390/ijms20163940

DO - 10.3390/ijms20163940

M3 - Review article

C2 - 31412614

AN - SCOPUS:85071167624

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 16

M1 - 3940

ER -